

**Tabla 5.** Analysis of the % of adverse events and calculation of the NNH in each study.

REHEARSAL	1st AUTHOR	DIARRHEA				VOMITING				ABDOMINAL PAIN				PANCREATITIS				GALLBLADDER PATHOLOGY				BREAST CANCER				THYROID CANCER				PSYCHIATRIC PATHOLOGY				SERIOUS			
		% GI	% GC	NNH	95% CI	% GI	% GC	NNH	95% CI	% GI	% GC	NNH	95% CI	% GI	% GC	NNH	95% CI	% GI	% GC	NNH	95% CI	% GI	% GC	NNH	95% CI	% GI	% GC	NNH	95% CI	% GI	% GC	NNH	95% CI	% GI	% GC	NNH	95% CI
<b>TEST ↓ WEIGHT F VS PLACEBO</b>																																					
<b>SCALE</b>	Pi-Sunyer 2015	24	12	9	7-11	19	5	7	6-9	14	9	21	15-38	0.3	0.1	414	-	2	1	61	42-123	0.4	0.2	414	-	0.1	0.0	829	-	0.1	0.2	2491	-	6	5	83.0	37-246
<b>STEP-1</b>	Wilding 2021	31	16	6	5-9	25	7	6	5-7	19	11	12	9-19	0.2	0.0	653	-	2	0.2	73	45-205	0.2	0.2	1298	-	0.1	0.0	1306	-	0.2	0.0	435	-	10	6	29.0	17-129
<b>STEP-3</b>	Wadden 2021	36	22	7	5-16	27	11	6	4-10	21	7	7	5-12	NC	NC	NC	-	3	0.0	31	19-108	0.2	0.5	-409	-	0.2	0.0	407	-	0.2	0.0	407	-	9	3	16.0	10-49
<b>STEP-5</b>	Garvey 2022	35	24	9	5-105	30	5	4	3-6	28	9	5	4-10	NC	NC	NC	-	3	0.0	38	-	0.0	1	-76	-	NC	NC	NC	-	6	8	-51	-	8	12	-26.0	9-34
<b>SURMOUNT-3</b>	Wadden 2023	31	9	5	4-7	18	1	6	5-8	10	2	12	8-24	0.3	0.3		-	2	1	94	-	2	1	140	-	2	1	140	-	21	19	41	-	6	5	91.0	-
<b>WEIGHT RECOVERY TRIALS</b>																																					
<b>STEP-4</b>	Rubino 2021	14	7	14	9-37	10	3	14	10-29	10	4	17	11-47	NC	NC	NC	-	1	1	267	-	1	0.0	178	-	NC	NC	NC	-	NC	NC	NC	-	8	6	48.0	18-53
<b>SURMOUNT-4</b>	Aronne 2023	NC	NC	NC	-	NC	NC	NC	-	NC	NC	NC	-	NC	NC	NC	-	NC	NC	NC	-	NC	NC	NC	-	NC	NC	NC	-	NC	NC	NC	-	3	3	-	-
<b>HEAD TO HEAD WEIGHT TRIALS</b>																																					
<b>STEP-8</b>	Rubino 2022 (sema vs lira)	28	18	10	NS	25	21	20	NS	6	4	42	NS	NC	NC	NC	NC	1	3	-42	NS	1	2	-128	NS	NC	NC	NC		6	15	-11	-6 - -49	8	11	-32.0	NS
<b>CLINICAL OUTCOME TRIALS</b>																																					
<b>SELECT</b>	Lincoff 2023	14	6	12	11-14	14	6	12	11-14	14	6	12	11-14	0.2	0.3		-	3	2	205	105-4609	5	5	2254	-	5	5	2254	-	6	7	59	42-98	33	36	-33.0	-23-(-63)

**GI** Intervention group. **GC** Control group. **NC** Not stated.

Note: The data in this table come from ClinicalTrials.gov (except SELECT which does not have results published on that page). SAEs come from published studies.

SURMOUNT-3 and SELECT do not differentiate the types of neoplasm (gives grouped data) and SELECT does not differentiate gastrointestinal pathology.

Note: NNH has been calculated with the data in table 2 (people who initiated tto) and the data in this table.